Earn CME for related activities: In this presentation from the 2019 Great Debates & Updates in Explore the latest advancements in relapsed/refractory multiple myeloma research here: Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hema
Elotuzumab in Relapsed/Refractory Multiple Myeloma Venetoclax (Ven), an oral agent that targets the antiapoptotic protein, BCL-2, has demonstrated efficacy, as monotherapy and
Emerging Therapies for Relapsed/Refractory Multiple Myeloma Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma - Krina Patel, MD, MSc | RT Irvine, CA Nov 5, 2022 Thomas G. Martin, MD discusses factors that impact his selection of continuation therapy after induction, including comorbidities, Watch the full course and our most up-to-date content here: Create a free account to track
Relapsed refractory multiple myeloma: a comprehensive overview Treatment Approach in Relapsed/Refractory Multiple Myeloma Latest Cancer Treatments in Relapsed/Refractory Multiple Myeloma | Ask the MD | The Patient Story
Welcome to the Quick Guide to Treatment for Relapsed and Refractory Multiple Myeloma. This Quick Guide will explain what is Dr. Costa on an Unmet Needs in Relapsed/Refractory Multiple Myeloma
Dr. Sherilyn Tuazon, a hematologist/oncologist from Seattle Cancer Care Alliance speaks on multiple myeloma at the 7th These relapses usually present aggressively, with similar dismal outcomes from refractory disease, defined as progression under treatment or Management of relapsed/refractory myeloma
Optimising the management of multiple myeloma in the early relapsed/refractory setting Multiple Myeloma | Treatment for Multiple Myeloma | LLS Sagar Lonial, MD, FACP, discusses the current treatment of RRMM and highlights the importance of BCMA [B-cell maturation
The HealthTree Foundation for Multiple Myeloma brings information from the experts to the patients! Learn more at We carry out integrative clinical sequencing of 511 relapsed, refractory multiple myeloma (RRMM) patients to define the disease's molecular alterations Treatment for Relapsed/Refractory Multiple Myeloma
Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma This video is episode 2 in our educational series, "Newest Treatment for Multiple Myeloma," made especially for multiple myeloma Peter Voorhees, MD: Approach to Relapsed/Refractory Multiple Myeloma: MCRT Charlotte 2018
Emerging Combinations for Relapsed/Refractory Multiple Myeloma Antibodies for Relapsed/ Refractory Multiple Myeloma FAQs on Multiple Myeloma Following Relapse Mary DeRome, Senior Director of Medical Communications and Education at the
Experts discuss factors that help determine treatment of relapsed/refractory multiple myeloma, including the role of cytogenetics, Recorded on 12/4/2021 70 year old male with relapsed/refractory multiple myeloma with t(11;14) translocation Summary: - For a Caitlin Costello, MD, associate clinical professor of medicine, University of California, San Diego, discusses the future of
Refractory myeloma is cancer that does not respond to treatment. After a time, almost all myeloma patients will experience relapse, which means the cancer Relapsed and Refractory Multiple Myeloma - StatPearls - NCBI
Early relapse myeloma is an exciting area of new research — including the potential return of Blenrep based on promising Relapse of myeloma is defined as the reappearance of signs and symptoms after a period of improvement. Relapsed/Refractory Multiple Myeloma: Switching Therapy
Overview of the Tourmaline-MM1 study in relapsed/refractory multiple myeloma Madhav Dhodapkar, MD, and Ivan Marques Borrello, MD discuss the use of monoclonal antibody, elotuzumab, in individuals with Research Guiding the Care of Patients with Relapsed/Refractory Multiple Myeloma
Defining Relapsed and Refractory Myeloma; what's the difference? Early relapse myeloma is an exciting area of new research
At the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Relapsed refractory MM (RRMM) is defined as a progressive disease, poor response despite treatment, progression within 60 days of the most recent treatment. Dr. Mateos on Ixazomib-Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma
Shaji Kumar, MD; Heinz Ludwig, MD; and Maria Victoria Mateos, MD, PhD, discuss preferred regimens for relapsed or refractory Treatment & Management of Relapsed/Refractory Myeloma In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the
Filmed on location in Barcelona, Spain during the 11th European Congress on Hematologic Malignancies, this webcast is part of Prof Meletios-Athanasios (Thanos) C Dimopoulos from Alexandra Hospital in Athens, Greece, Dr Hans Lee from Sarah Cannon Patients with relapsed/refractory (R/R) multiple myeloma (MM) are often frail with preexisting comorbidities and poor performance status (PS).
Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Relapsed/Refractory Deepu Madduri: Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Barry A. Paul, MD, discusses the role of carfilzomib in the treatment of patients with relapsed/refractory multiple myeloma. Website: Updates on Therapeutic Strategies in the Treatment of Relapsed Management of Relapse/Refractory Multiple Myeloma
The genetic heterogeneity and drug resistance mechanisms of Panelists Keith Stewart, MB, ChB; Ivan M. Borrello, MD; Saad Z. Usmani, MD; Thomas G. Martin, MD; Sagar Lonial, MD; and
RRMM can refer to patients who relapse early after first-line treatment, as well as to patients who relapse after several lines of therapy Paul Richardson, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses his highlights of the 20th Congress of the European
Treatment options for high risk relapsed/refractory multiple myeloma Treatment for Relapsed and Refractory Multiple Myeloma In this segment, Noopur Raje, MD and Sagar Lonial, MD discuss treatment options for patients with relapsed or refractory multiple
Jeffrey A. Zonder, MD, Hematologist-Oncologist from the Barbara Ann Karmanos Cancer Institute in Detroit, Michigan, describes A review of the treatment evolution in relapsed/refractory multiple myeloma
Relapsed Refractory Multiple Myeloma | Current Treatment Options | Options on the Horizon Management of Relapsed/Refractory Multiple Myeloma Hot Topics on Relapsed/Refractory Multiple Myeloma from the 63rd ASH Annual Meeting*
ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma Relapsed/Refractory Multiple Myeloma: A Review of Available A conversation on current trails with multiple myeloma including CANDOR and IKEMA; understanding the role of anti-CD38
Considerations for switching between IMiD-based therapy and proteasome inhibitors, as well as incorporating in a monoclonal What is relapsed and refractory myeloma? | Experts Explain #myeloma Relapses are, unfortunately, common after first-line treatment. While the prognosis for relapsed refractory multiple myeloma is generally poor, advances in the
Outcomes in frail patients receiving BCMA-directed bispecific "Refractory myeloma" is disease that is non-responsive to therapy or progresses within 60 days of the last line of therapy [2]. "Relapsed National Conference 2018 - Presented by Dr Joseph Mikhael For more information about multiple myeloma, visit myeloma.ca.
Experts begin their discussion on evolving treatment strategies in the setting of relapsed or refractory multiple myeloma. Dr. Costello on the Future of Isatuximab in Relapsed/Refractory Multiple Myeloma Advances in Relapsed/Refractory Multiple Myeloma: Insights From Dr. Rahul Banerjee
Multiple Myeloma: Combination Therapy for Relapsed/Refractory Patients Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, outlines the current treatment strategies of Recent drug approvals for the treatment of relapsed/refractory multiple myeloma
Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the The anti-CD38 monoclonal antibody daratumumab had a favorable safety profile with manageable infusion-related reactions, Sundar Jagannath, MD, reviews the key findings from clinical trials that studied newer and investigational therapies in
Maria-Victoria Mateos, MD, PhD; Jatin J. Shah; and Andrew Spencer, MD, discuss their treatment approaches in the Relapsed Refractory Multiple Myeloma (RRMM) Glossary Optimal treatment sequencing for relapsed/refractory myeloma
Dr. Paul on the Role of Carfilzomib in Relapsed/Refractory Multiple Myeloma In a recent interactive webinar, renowned experts Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy and
Defining relapsed and refractory MM: the challenges and In the first portion, hosted by Nina Shah, MD, Professor of Clinical Medicine, Multiple Myeloma Translational Initiative, Division of From new FDA-approved drugs and combinations to the latest in #immunotherapy, there is a lot shifting in the landscape of
Long-Term (≥5-Year) Remission and Survival After Treatment With Dr Rifkin (Rocky Mountain Cancer Center, Denver, USA) chairs an expert panel discussion with Prof Lonial (Emory Cancer
Treatment Options in Relapsed/Refractory Multiple Myeloma Philippe Moreau, MD, Nantes University Hospital, Nantes, France, talks on optimizing the treatment sequence for patients with
Multiple Myeloma: Newest Treatments for Relapsed/Refractory MM | For Patients & Caregivers ICAHO19 - Multiple Myeloma session: relapsed/refractory myeloma Luciano J. Costa, MD, PhD, an associate professor of medicine in the Blood and Marrow Transplantation and Cell Therapy
Dr. Voorhees talks about the treatment of early relapse and late relapse myeloma, emerging therapies and guidelines for how to Certified AMA Activity - Clinical Clips The management of relapsed/refractory multiple myeloma (RRMM) is rapidly evolving due to Watch a top panel of experts explore and interpret the current data and perspectives on the management of GEP-NETs through
Relapsed/Refractory Multiple Myeloma: Optimal Therapy Expert Cancer Panel: Relapsed/refractory multiple myeloma with t(11;14) translocation
Emerging Therapeutic Options for Relapsed/Refractory Multiple Myeloma The evolving treatment paradigm for relapsed/refractory multiple myeloma
Daratumumab Safe in Relapsed/Refractory Multiple Myeloma Patients Optimal treatment approaches and considerations for sequencing therapy in patients with relapsed/refractory multiple myeloma.
FAQs on Multiple Myeloma Following Relapse CARTITUDE-1 evaluated ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM). Treatment Decisions in Relapsed/Refractory Multiple Myeloma
Dr James Berenson talks to ecancer at the International Myeloma Workshop 2019 about a trial looking at elotuzumab in Treatment Landscape for Relapsed and Refractory Multiple Myeloma Trials in Relapsed/Refractory Multiple Myeloma